Looking forward to meeting BC’s top talent and sharing what it’s like to be a scientist at Aspect Biosystems. Stop by and say hi to our team on Friday!

February 2023 ❄️

Can methylation of histone H3 lysine 4 (H3K4) affect the maintenance of mature #BetaCell function? In this study, researchers at the Hoffman Lab report sustained methylation of H3K4 is critical for the maintenance of beta cell function. BC Children's Hospital Research Institute ➡️ bit.ly/3yLVhsK

This is the future. Aspect Biosystems is using 3D printing technology to fight diabetes. Today I announced over $25 million to help them and 9 other local businesses continue to innovate and develop #bctech that will improve the lives of people worldwide.

Proud to announce with Minister Harjit Sajjan over $25.7M for 10 Vancouver businesses & organizations that fuel our economy, create jobs, and improve lives in our community. We're committed to growing talent and businesses at home in Vancouver and Canada, and around the world.

👨‍🔬🤝👩‍🔬Learn now #EDI programs are improving research opportunities and engaging #stemcell students Explore the program, learn more, and register for free 👉 bit.ly/3JaIGoI New York Stem Cell Foundation Research Institute Duke University School of Medicine USC Stem Cell Icahn School of Medicine at Mount Sinai

Aspect Biosystems Receives Over $3.6 Million from the Government of Canada via Pacific Economic Development Canada Read the full press release here: hubs.li/Q01HKfct0 #BCTech #CdnInnovation

Vertex Pharmaceuticals and CRISPR Therapeutics have announced a non-exclusive licensing agreement for the use of #CRISPR Cas9 gene editing technology to accelerate the development of Vertex’s hypoimmune cell therapies for #type1diabetes. businesswire.com/news/home/2023…

#PRESS Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity

We are excited to announce a partnership with Novo Nordisk to develop bioprinted tissue therapeutics for diabetes and obesity. Learn more: hubs.li/Q01L5Fd_0

Novo Nordisk taps into Canadian biotech’s cell therapies for diabetes and obesity in deal worth up to $2.6B - endpts.com/novo-nordisk-t… via Endpoints News

Today Aspect Biosystems and Novo Nordisk announced a US $2.6B partnership to develop bioprinted tissue therapeutics for #diabetes and #obesity – a game-changing investment into the life sciences sector made possible in part by #research funded by SCN. stemcellnetwork.ca/scn-industry-p…

Heading to LA for #ASGCT23 next week with the Aspect Biosystems liver team! Let's connect to chat about bioprinted tissue therapeutics.

We are presenting new preclinical data on our bioprinted liver tissue platform at the American Society of Gene & Cell Therapy Annual Meeting 2023. #ASGCT23 Learn more: hubs.li/Q01PWlTJ0

We are presenting three posters at #ASGCT23 in Los Angeles, CA this week. Learn more about each poster below 👇🧵 #CellTherapy #Bioprinting #LiverDisease

The team had an amazing time presenting new preclinical data on our bioprinted liver tissue platform at #ASGCT23! Thank you to everyone who stopped by to learn more.

Excited to learn about the latest and greatest in stem cell biology at #ISSCR2023 in Boston next week. Our Aspect Biosystems team is growing and we are looking for scientists and engineers to help us develop bioprinted tissue therapeutics. Let's connect if you are interested!

This is what I want to do when I grow up 🙌🏻

The ISSCR is proud to honor Dr. Takanori Takebe as the recipient of the 2023 ISSCR Outstanding Young Investigator Award for his exceptional achievements in the early part of his independent career in stem cell research. #ISSCR2023